

This is the English translation of a Japanese press release published on April 17, 2026. If there are any differences in content or interpretation, the Japanese version shall prevail.

April 17, 2026

To Whom It May Concern:

Company name: Hisamitsu Pharmaceutical Co., Inc.
Representative: Kazuhide Nakatomi, President & CEO
(TSE Prime, NSE Premier and FSE Code No. 4530)
Contact: Ken Sakai, Section Manager
Public Relations Section
(TEL: 03-5293-1704)

**Notice Concerning Approval of Share Consolidation, Abolition of Provisions on Share Units,
and Partial Amendment of the Articles of Incorporation**

Hisamitsu Pharmaceutical Co., Inc. (the “Company”) hereby announces that, as announced in the Company’s press release dated March 13, 2026 entitled “Notice Concerning the Convocation of an Extraordinary General Shareholders’ Meeting Regarding Share Consolidation, Abolition of Provisions on Share Units, and Partial Amendment of the Articles of Incorporation” (the “Company’s Press Release”), the Company submitted Proposal No. 1, “Share Consolidation,” and Proposal No. 2, “Partial Amendment to the Articles of Incorporation,” to the extraordinary general shareholders’ meeting held today (the “Extraordinary General Shareholders’ Meeting”), and each of these proposals was approved and adopted as originally proposed, as set forth below.

As a result, the Company’s common stock (the “Company’s Stock”) will fall under the delisting criteria of Tokyo Stock Exchange, Inc. (the “TSE”), Nagoya Stock Exchange, Inc. (the “NSE”), and Fukuoka Stock Exchange (the “FSE”). Accordingly, the Company’s Stock is expected to be designated as securities under supervision from today until May 10, 2026, and to be delisted as of May 11, 2026. After the delisting, the Company’s Stock will no longer be tradable on the Prime Market of the TSE, the Premier Market of the NSE, or the Main Market of the FSE. Shareholders are kindly requested to take note of this matter.

1. Proposal No. 1 (Share Consolidation)

The Company obtained approval from the shareholders at the Extraordinary General Shareholders’ Meeting for the share consolidation described below (the “Share Consolidation”). For details of the Share Consolidation, please refer to the Company’s Press Release.

(1) Class of Shares to Be Consolidated

Common stock

(2) Consolidation Ratio

The Company's Stock will be consolidated at a ratio of one (1) share for every 23,467,182 shares of the Company's Stock.

(3) Reduction in the Total Number of Issued Shares

70,401,544 shares

(4) Total Number of Issued Shares Before the Effective Date

70,401,547 shares

(Note) At the meeting of its board of directors held on March 13, 2026, the Company resolved to cancel 4,763,348 shares of treasury stock as of May 12, 2026 (which corresponds to all treasury shares held by the Company as of February 28, 2026). Accordingly, the "total number of issued shares before the effective date" stated above reflects the number of issued shares after such cancellation.

(5) Total Number of Issued Shares After the Effective Date

3 shares

(6) Total Number of Authorized Shares as of the Effective Date

12 shares

(7) Treatment of Fractional Shares and Amount of Cash Expected to Be Delivered to Shareholders as a Result of Such Treatment

- (I) Whether the treatment is to be conducted pursuant to Article 235, Paragraph 1 of the Companies Act or Article 234, Paragraph 2 thereof as applied mutatis mutandis pursuant to Article 235, Paragraph 2 of the Companies Act, and the reasons therefor

As a result of the Share Consolidation, the number of shares of the Company's Stock held by shareholders other than TAIYO KOSAN CO., INC. (the "Offeror"), Mr. Kazuhide Nakatomi, TKY CO., INC. ("TKY"), Nakatomi Asset Management Co., Inc. ("Nakatomi Asset Management"), SSTM CO., INC. ("SSTM"), STM CO., INC. ("STM"), TM CO., LTD. ("TM"), and Nakatomi Kosan Co., Inc. ("Nakatomi Kosan") (Mr. Kazuhide Nakatomi, TKY, Nakatomi Asset Management, SSTM, STM, TM, and Nakatomi Kosan are hereinafter collectively referred to as the "Non-tendering Shareholders")

is expected to be less than one (1) share.

With respect to the treatment of fractions of less than one (1) share arising from the Share Consolidation, the aggregate number of such fractional shares (and if such aggregate number includes a fraction of less than one (1) share, such fraction shall be rounded down pursuant to the provisions of Article 235, Paragraph 1 of the Companies Act (Act No. 86 of 2005, as amended; the “Companies Act”)) will be sold in accordance with the provisions of Article 235 of the Companies Act and other applicable laws and regulations, and the proceeds obtained from such sale will be distributed to the shareholders who hold such fractional shares in proportion to the respective fractions held by them.

With respect to such sale procedures, in light of the fact that the Share Consolidation is to be implemented as part of a transaction aimed at taking the Company private through the acquisition of all of the Company’s Stock (including any shares of the Company’s Stock issuable upon exercise of the Share Acquisition Rights (Note 1), but excluding the treasury shares held by the Company and the Non-tendered Shares (Note 2)), the Share Acquisition Rights, and the American Depositary Receipts (Note 3) (the “Transaction”), that the Company’s Stock is scheduled to be delisted as of May 11, 2026 and will thereafter constitute shares without a market price, and that it is therefore considered unlikely that a purchaser will appear through an auction, the Company plans to sell the number of shares equivalent to the aggregate number of such fractional shares to the Offeror, upon obtaining permission from the court pursuant to the provisions of Article 234, Paragraph 2 of the Companies Act as applied mutatis mutandis pursuant to Article 235, Paragraph 2 thereof.

With respect to the sale price in such case, if the required court permission is obtained as scheduled, the Company plans to set the sale price so that shareholders listed or recorded in the Company’s final shareholder register as of May 12, 2026, which is the day immediately preceding the effective date of the Share Consolidation, will receive cash in an amount equivalent to the number of shares of the Company’s Stock held by such shareholders multiplied by 6,082 yen, which is the same amount as the purchase price per share of the Company’s Stock in the tender offer conducted by the Offeror for the Company’s Stock, the Share Acquisition Rights, and the American Depositary Receipts during the period from January 7, 2026 to February 19, 2026.

However, if the court permission is not obtained, or if adjustments due to fractional calculations are required, the actual amount of cash delivered may differ from the amount described above.

(Note 1)

“Share Acquisition Rights” means, collectively, the following share acquisition rights (i) through (xi):

- (i) The share acquisition rights issued pursuant to the resolution of the meeting of the Company’s board of directors held on July 10, 2015 (Exercise period: July 28, 2015 to July 27, 2065)

- (ii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 8, 2016 (Exercise period: July 26, 2016 to July 25, 2066)
- (iii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 7, 2017 (Exercise period: July 26, 2017 to July 25, 2067)
- (iv) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 6, 2018 (Exercise period: July 25, 2018 to July 24, 2068)
- (v) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 10, 2019 (Exercise period: July 27, 2019 to July 26, 2069)
- (vi) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 9, 2020 (Exercise period: July 29, 2020 to July 28, 2070)
- (vii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 8, 2021 (Exercise period: July 27, 2021 to July 26, 2071)
- (viii) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 7, 2022 (Exercise period: July 26, 2022 to July 25, 2072)
- (ix) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 13, 2023 (Exercise period: August 1, 2023 to July 31, 2073)
- (x) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 11, 2024 (Exercise period: July 30, 2024 to July 29, 2074)
- (xi) The share acquisition rights issued pursuant to the resolution of the meeting of the Company's board of directors held on July 10, 2025 (Exercise period: July 29, 2025 to July 28, 2075)

(Note 2)

"Non-tendered Shares" means an aggregate of 4,044,142 shares of the Company's Stock held by the Non-tendering Shareholders (Note 4).

(Note 3)

"American Depositary Receipts" means the American depository receipts issued in the United States by Citibank, N.A. and representing the Company's Stock.

(Note 4)

Mr. Kazuhide Nakatomi, TKY, Nakatomi Asset Management, STM, and TM indirectly hold fractional shares through the cumulative stock investment plan. As these fractional shares are held in the name of a securities company, the number of shares of the Company's Stock held by Mr. Kazuhide Nakatomi, TKY, Nakatomi Asset Management, STM, and TM does not include these fractional shares.

(II) Name of the Person Expected to Purchase the Shares Subject to Sale

TAIYO KOSAN CO., INC. (the Offeror)

(III) Method by Which the Person Expected to Purchase the Shares Subject to Sale Will Secure Funds for Payment of the Purchase Price and the Reasonableness of Such Method

According to the Offeror, it plans to fund the acquisition of the Company's Stock corresponding to the aggregate number of fractions of less than one (1) share arising from the Share Consolidation through borrowings from Sumitomo Mitsui Banking Corporation and MUFG Bank, Ltd. In the course of implementing the procedures for the Transaction, the Company confirmed that the Offeror had secured the necessary funds by reviewing the tender offer registration statement submitted by the Offeror on January 7, 2026, as well as the loan commitment letters and equity commitment letters attached thereto. In addition, according to the Offeror, no event has occurred since that date that would hinder the payment of the consideration for the sale of the Company's Stock corresponding to the aggregate number of fractions of less than one (1) share arising from the Share Consolidation, nor does the Offeror recognize any possibility that such an event will occur in the future. Based on the foregoing, the Company has determined that the method by which the Offeror will secure the funds necessary to pay the consideration for the sale of the Company's Stock corresponding to the aggregate number of fractions of less than one (1) share arising from the Share Consolidation is reasonable.

(IV) Expected Timing of the Sale and the Delivery of the Proceeds to Shareholders

The Company plans, around late May to early June 2026, to file a petition with the court seeking permission to sell the Company's Stock corresponding to the aggregate number of fractions of less than one (1) share arising from the Share Consolidation, pursuant to the provisions of Article 234, Paragraph 2 of the Companies Act as applied mutatis mutandis pursuant to Article 235, Paragraph 2 thereof. Although the timing of obtaining such court permission may vary depending on the status of the court and other factors, the Company expects to obtain the court permission and sell such Company's Stock to the Offeror around mid- to late June 2026. Thereafter, following the completion of the necessary preparations for the delivery of the proceeds of such sale to shareholders, the

Company expects to deliver such proceeds to shareholders around mid-August 2026. Taking into account the period required for a series of procedures related to the sale from the effective date of the Share Consolidation, the Company has determined that the sale of the Company's Stock corresponding to the aggregate number of fractions of less than one (1) share arising from the Share Consolidation, and the delivery of the proceeds thereof to shareholders, will be carried out at the respective times described above.

2. Proposal No. 2 (Partial Amendment to the Articles of Incorporation)

The Company obtained approval from the shareholders at the Extraordinary General Shareholders' Meeting for the following partial amendments to the Company's articles of incorporation. For details of such amendments, please refer to the Company's Press Release.

These partial amendments to the articles of incorporation are scheduled to become effective on May 13, 2026, which is the effective date of the Share Consolidation, subject to the Share Consolidation becoming effective.

- (1) If the Share Consolidation becomes effective, the total number of authorized shares of the Company will be reduced to 12 shares in accordance with the provisions of Article 182, Paragraph 2 of the Companies Act. In order to clarify this point, Article 5 (Total Number of Authorized Shares) of the Articles of Incorporation will be amended on the condition that the Share Consolidation takes effect.
- (2) If the Share Consolidation becomes effective, the Company's Stock is expected to be delisted, and, following the delisting, the Company's Stock will no longer be tradable on the Prime Market of the TSE, the Premier Market of the NSE, or the Main Market of the FSE. Accordingly, subject to the Share Consolidation becoming effective, the Company will delete Article 6 (Acquisition of Treasury Shares) of the Articles of Incorporation in its entirety and renumber the subsequent articles accordingly.
- (3) If the Share Consolidation becomes effective, the total number of issued shares of the Company will be three (3) shares, and it will therefore no longer be necessary to provide the share unit system. Accordingly, subject to the Share Consolidation becoming effective, the Company will abolish the current share unit system, under which one (1) unit consists of 100 shares, by deleting Article 7 (Share Units) and Article 8 (Restrictions on the Rights of Holders of Shares Less Than One Unit) of the Articles of Incorporation in their entirety, and partially deleting Article 10 (Regulations on Handling of Shares), and renumber the subsequent articles accordingly.
- (4) If the Share Consolidation becomes effective, the Company's shareholders will be limited to the Offeror and the Non-tendering Shareholders only, and, as a result of the implementation

of the Share Consolidation, the Company's Stock will be delisted. Accordingly, the provisions regarding the record date for the annual general shareholders' meeting and the provisions regarding the electronic provision system for shareholders' meeting materials will no longer be necessary. Therefore, subject to the Share Consolidation becoming effective, the Company will delete Article 11 (Record Date) and Article 14 (Electronic Provision Measures, etc.) of the Articles of Incorporation in their entirety and renumber the subsequent articles accordingly.

3. Schedule of the Share Consolidation

(i) Date for the Extraordinary General Meeting of Shareholders	April 17, 2026 (Friday) (Scheduled)
(ii) Date of Designation as Securities Under Supervision	April 17, 2026 (Friday) (Scheduled)
(iii) Last Trading Day of the Company's Stock	May 8, 2026 (Friday) (Scheduled)
(iv) Delisting Date of the Company's Stock	May 11, 2026 (Monday) (Scheduled)
(v) Effective Date of the Share Consolidation	May 13, 2026 (Wednesday) (Scheduled)